https://orcid.org/0000-0002-9099-420X
References
- Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, Hosein Z, Padda I, Mangat J, Altaf M. Comorbidity and its impact on patients with COVID-19. SN Compr Clin Med. 2020;2(8):1–11. doi:10.1007/s42399-020-00363-4.
- Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020;586(7830):516–27. doi:10.1038/s41586-020-2798-3.
- Chen W-H, Wei J, Kundu RT, Adhikari R, Liu Z, Lee J, Versteeg L, Poveda C, Keegan B, Villar MJ, et al. Genetic modification to design a stable yeast-expressed recombinant SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidate. Biochim Biophys Acta Gen Subj. 2021;1865(6):129893. doi:10.1016/j.bbagen.2021.129893.
- Pollet J, Chen W-H, Versteeg L, Keegan B, Zhan B, Wei J, Liu Z, Lee J, Kundu R, Adhikari R, et al. SARS‑CoV-2 RBD219-N1C1: a yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice. Human Vacc Immunother. 2021;17(8):2356–66. doi:10.1080/21645515.2021.1901545.
- Lee J, Liu Z, Chen W-H, Wei J, Kundu R, Adhikari R, Rivera JA, Gillespie PM, Strych U, Zhan B, et al. Process development and scale-up optimization of the SARS-CoV-2 receptor binding domain–based vaccine candidate, RBD219-N1C1. Appl Microbiol Biotechnol. 2021;105(10):4153–65. doi:10.1007/s00253-021-11281-3.
- Chen WH, Tao X, Agrawal AS, Algaissi A, Peng B-H, Pollet J, Strych U, Bottazzi ME, Hotez PJ, Lustigman S, et al. Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement. Vaccine. 2020;38(47):7533–41. doi:10.1016/j.vaccine.2020.09.061.
- Chen WH, Pollet J, Strych U, Lee J, Liu Z, Kundu RT, Versteeg L, Villar MJ, Adhikari R, Wei J, et al. Yeast-expressed recombinant SARS-CoV-2 receptor binding domain RBD203-N1 as a COVID-19 protein vaccine candidate. Protein Expr Purif. 2022;190:106003. doi:10.1016/j.pep.2021.106003.
- Yang J, Wang W, Chen Z, Lu S, Yang F, Bi Z, Bao L, Mo F, Li X, Huang Y, et al. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Nature. 2020;586(7830):572–7. doi:10.1038/s41586-020-2599-8.
- McAleer WJ, Buynak EB, Maigetter RZ, Wampler DE, Miller WJ, Hilleman MR. Human hepatitis B vaccine from recombinant yeast. Nature. 1984;307(5947):178–80. doi:10.1038/307178a0.
- Thuluva S, Paradkar V, Turaga K, Yerroju V, Mogulla R, Turaga K, Kyasani M, Manoharan SK, Medigeshi G, Singh J, et al. Selection of optimum formulation of RBD-based protein subunit COVID-19 vaccine (CORBEVAX™) based on safety and immunogenicity in an open-label, randomised Phase-1 and 2 clinical studies. EBioMedicine. 2022;83:104217. doi:10.1016/j.ebiom.2022.104217.
- LIAISON® SARS-CoV-2 S1/S2 IgG. The fully automated serology test for the detection of SARS-CoV-2 IgG Antibodies. [ accessed 2022 Mar 17]. https://www.diasorin.com/sites/default/files/allegati/liaisonr_sars-cov-2_s1s2_igg_brochure.pdf.pdf.
- Bewley KR, Coombes NS, Gagnon L, McInroy L, Baker N, Shaik I, St-Jean JR, St-Amant N, Buttigieg KR, Humphries HE, et al. Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays. Nat Protoc. 2021;16(6):3114–40. doi:10.1038/s41596-021-00536-y.
- Ambrosino D, Han HH, Hu B, Liang J, Clemens R, Johnson M, Siber G, Goldblatt D. Immunogenicity of SCB-2019 coronavirus disease 2019 vaccine compared with 4 approved vaccines. J Infect Dis. 2022;225(2):327–31. doi:10.1093/infdis/jiab574.
- Valneva reports positive phase 3 results for inactivated, adjuvanted COVID-19 vaccine candidate VLA2001. https://valneva.com/press-release/valneva-reports-positive-phase-3-results-for-inactivated-adjuvanted-covid-19-vaccine-candidate-vla2001/#:~:text=%7C%20DE-,Valneva%20Reports%20Positive%20Phase%203%20Results%20for%20Inactivated,COVID%2D19%20Vaccine%20Candidate%20VLA2001&text=VLA2001%20induced%20broad%20T%2Dcell,S%2C%20M%20and%20N%20proteins.